This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

EasyBand GOAL Trial

This study has been withdrawn prior to enrollment.
(This study was withdrawn to further optimize the device. No patients were enrolled in the trial.)
Information provided by:
Allergan Identifier:
First received: September 21, 2007
Last updated: October 3, 2014
Last verified: November 2010
Safety, effectiveness, and performance of Allergan's EasyBand telemetrically adjustable gastric banding device for the treatment of morbidly obese patients.

Condition Intervention
Morbid Obesity Device: Easyband (Telemetrically adjustable gastric banding device)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Percent excess weight loss (%EWL) [ Time Frame: 5 years ]

Enrollment: 0
Study Start Date: December 2010
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Easyband (Telemetrically adjustable gastric banding device)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Minimum 3 year history of morbid obesity with documented failure of conservative, non-surgical means of weight reduction within 1 year prior to the screening visit;
  • BMI >/= 40 kg/m2, or BMI >/= 35 kg/m2 and </= 40 kg/m2 with one or more significant medical conditions related to obesity;
  • Candidate for surgical weight loss intervention

Exclusion Criteria:

  • Previous surgical treatment of obesity;
  • Patient already implanted with a device sensitive to radiofrequency emissions (implantable pacemaker, implantable defibrillator, etc);
  • Physical or emotional conditions that may prohibit surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00534339

United States, California
USA, California, United States
Canada, Quebec
Canada, Quebec, Canada
Sponsors and Collaborators
Allergan Medical
Study Director: Allergan Medical Allergan Medical
  More Information

Responsible Party: Allergan Medical, Allergan Identifier: NCT00534339     History of Changes
Other Study ID Numbers: 10042
Study First Received: September 21, 2007
Last Updated: October 3, 2014

Additional relevant MeSH terms:
Obesity, Morbid
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on August 18, 2017